Leerink Partners downgraded Carbylan Therapeutics (NASDAQ: CBYL) from Outperform to Market Perform with a price target of $1.80 (from $15.00).Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change Downgrades

Wedbush Remains Bullish on Carbylan Therapeutics (CBYL) Despite Mixed Cor1.1 Results - PT to $14 February 2, 2016 1:49 PM Carbylan Therapeutics's (CBYL) Phase 3 Trial of Hydros-TA in Patients With OA of Knee Meets One Primary Endpoint, Misses Second Primary EndpointFebruary 1, 2016 4:29 PM